Tango Therapeutics Posts $68.4M Q3 Loss as Pipeline Costs Mount
TNGX has more than doubled off its 52-week low of $7.37.
Summary
Tango Therapeutics reported a $68.4M loss for the third quarter, or 39 cents a share, wider than the $55.3M loss it posted in Q2, with revenue dropping to zero on the end of its Gilead deal. The company ended the third quarter with $977.5M in cash, down from the $1.0B it held at the end of Q2 after a June equity raise, and it has a $400M at-the-market program in place, so the loss is not a near-term liquidity problem — but the burn is climbing while the clinical story carries the valuation. The quarter follows the October 23 disclosure of an 82% overall response rate in 22 heavily pretreated MTAP-deleted/RAS-mutant pancreatic cancer patients for vopimetostat plus daraxonrasib, and a strategic reprioritization that cut roughly 14% of the workforce.
At the time of this announcement, TNGX was trading at $21.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $7.37 to $34.39. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.